Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Con... (s were minor bleeds at the venous access...)

HOME >> MEDICINE >> TECHNOLOGY

Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008

Date:9/2/2008

s were minor bleeds at the venous access

site. The incidence of additional minor events, including headache,

dizziness, nausea, fatigue and hypotension, was similar to placebo.

"Our studies consistently have confirmed the two major attributes of the REG1 system, rapid anticoagulant activity and rapid and predictable reversal of this effect," stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado Biosciences. "Based on the encouraging Phase I study data, we anticipate results from our ongoing Phase IIa studies evaluating REG1 in

patients undergoing elective PCI will further confirm that REG1 has the potential to replace standard heparin therapy."

"In striving to meet the needs of individual patients in varied and oftentimes complex settings, it is essential for physicians to quickly, safely and effectively achieve the desired anticoagulation effect and, when required for specific clinical indications, to attenuate or fully reverse this effect," stated Richard C. Becker, M.D., Professor of Medicine, Duke University Medical Center, and Director, Duke Cardiovascular Thrombosis Center, Duke Clinical Research Institute. "As we enter a new era of anticoagulant pharmacotherapy, a therapeutic system offering these attributes would be of great benefit and may have a profound impact on patient care."

Clinician-scientists from the Duke Clinical Research Institute (DCRI) and Regado evaluated REG1 in three Phase I studies: Phase Ia, a healthy volunteer drug dose-escalating pharmacokinetic-pharmacodynamic (PK-PD) study; Phase Ib, a drug dose-escalating study in subjects with stable coronary artery disease who were receiving aspirin with or without clopidogrel; and Phase Ic, a multiple exposure, dose-ranging study in 39 healthy volunteers. Top-line results from these three studies were presented last year at the American Heart Association's 2007 Scientific Sessions and subsequently published in top-tier scientifi
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501

Post Your Comments:

Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Con...(s were minor bleeds at the venous access...),Health